Pharvaris Announces Annual Meeting of Shareholders

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases like hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), has scheduled its annual general meeting of shareholders. The meeting will take place on June 27, 2025, at 16:00 CEST (10:00 a.m. EDT). Shareholders can access all relevant meeting documents and information in the "Investors" section of Pharvaris' website under "Events & Presentations" and on the SEC's website. Interested shareholders must register to attend as outlined in the meeting notice and agenda.

News Market Reaction

+0.50%

1 alert

+0.50% News Effect

On the day this news was published, PHVS gained 0.50%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ZUG, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders will take place on Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT).

All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the “Investors” section of Pharvaris’ website under “Events & Presentations”. The documents will also be made available on the SEC’s website at www.sec.gov. Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.

About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit https://pharvaris.com/.

Contact
Maggie Beller
Executive Director, Head of Corporate and Investor Communications
maggie.beller@pharvaris.com

FAQ

When is Pharvaris (PHVS) 2025 annual shareholder meeting?

Pharvaris' 2025 annual shareholder meeting is scheduled for Friday, June 27, 2025, at 16:00 CEST (10:00 a.m. EDT).

What diseases does Pharvaris (PHVS) focus on treating?

Pharvaris focuses on developing treatments for bradykinin-mediated diseases, specifically hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).

How can shareholders access Pharvaris (PHVS) annual meeting documents?

Shareholders can access meeting documents in the 'Investors' section under 'Events & Presentations' on Pharvaris' website or on the SEC's website at www.sec.gov.

What type of medications is Pharvaris (PHVS) developing?

Pharvaris is developing novel, oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases.